IL165562A0 - Prodrugs of imidazole derivatives for use as proton pump inhibitors in the treatment of e.g. peptic ulcers - Google Patents

Prodrugs of imidazole derivatives for use as proton pump inhibitors in the treatment of e.g. peptic ulcers

Info

Publication number
IL165562A0
IL165562A0 IL16556204A IL16556204A IL165562A0 IL 165562 A0 IL165562 A0 IL 165562A0 IL 16556204 A IL16556204 A IL 16556204A IL 16556204 A IL16556204 A IL 16556204A IL 165562 A0 IL165562 A0 IL 165562A0
Authority
IL
Israel
Prior art keywords
prodrugs
treatment
proton pump
imidazole derivatives
pump inhibitors
Prior art date
Application number
IL16556204A
Other languages
English (en)
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of IL165562A0 publication Critical patent/IL165562A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16556204A 2002-06-14 2004-12-05 Prodrugs of imidazole derivatives for use as proton pump inhibitors in the treatment of e.g. peptic ulcers IL165562A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002175086 2002-06-14
JP2003041085 2003-02-19
PCT/JP2003/007546 WO2003105845A1 (en) 2002-06-14 2003-06-13 Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers

Publications (1)

Publication Number Publication Date
IL165562A0 true IL165562A0 (en) 2006-01-15

Family

ID=29738411

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16556204A IL165562A0 (en) 2002-06-14 2004-12-05 Prodrugs of imidazole derivatives for use as proton pump inhibitors in the treatment of e.g. peptic ulcers

Country Status (19)

Country Link
US (2) US7410981B2 (xx)
EP (2) EP1513527B1 (xx)
JP (1) JPWO2003106429A1 (xx)
KR (1) KR20050009751A (xx)
CN (1) CN1678315A (xx)
AR (1) AR040221A1 (xx)
AT (1) ATE437642T1 (xx)
AU (2) AU2003242388A1 (xx)
BR (1) BR0311801A (xx)
CA (2) CA2489470A1 (xx)
DE (1) DE60328603D1 (xx)
IL (1) IL165562A0 (xx)
MX (1) MXPA04012396A (xx)
NO (1) NO20050141L (xx)
OA (1) OA12867A (xx)
PE (1) PE20040563A1 (xx)
PL (1) PL373085A1 (xx)
TW (1) TW200307544A (xx)
WO (2) WO2003106429A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176319B2 (en) 2004-04-28 2007-02-13 Hetero Drugs Limited Process for substituted sulfoxides
EP2275088B2 (en) 2005-02-25 2018-09-26 Takeda Pharmaceutical Company Limited Method for producing granules
KR101148399B1 (ko) * 2005-06-22 2012-05-23 일양약품주식회사 항궤양제 및 점막보호제를 함유하는 경구용 위장질환치료용 약제 조성물
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
WO2009105568A1 (en) 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
CA2778115C (en) 2009-10-28 2016-04-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2016172436A1 (en) * 2015-04-23 2016-10-27 Temple University-Of The Commonwealth System Of Higher Education Polycationic amphiphiles and polymers thereof as antimicrobial agents and methods using same
ES2836500T3 (es) * 2016-06-21 2021-06-25 Univ Columbia Inhibidores de aldosa reductasa y métodos de uso de los mismos
WO2018081347A1 (en) 2016-10-26 2018-05-03 Temple University-Of The Commonwealth System Of Higher Education Polycationic amphiphiles as antimicrobial agents and methods using same
MX2020001057A (es) 2017-07-28 2020-11-24 Applied Therapeutics Inc Composiciones y metodos para tratar la galactosemia.
US11767311B2 (en) * 2020-06-17 2023-09-26 Ildong Pharmaceutical Co., Ltd. Acid secretion inhibitor and use thereof
IT202200001022A1 (it) * 2022-01-21 2023-07-21 Exo Lab Italia Composti farmaceutici ibridi ottenuti mediante coniugazione di un inibitore delle pompe protoniche e un inibitore delle anidrasi carboniche

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE8300736D0 (sv) 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
KR890000387B1 (ko) 1984-09-24 1989-03-16 디 엎존 캄파니 2-(피리딜알켄술 피닐)벤즈 이미드아졸류의 n-치환 유도체의 제조방법
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
US4965269A (en) 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
DE19832060C2 (de) * 1998-07-16 2000-07-06 Siemens Ag Doppelbare Prozessoreinrichtung
US6542966B1 (en) * 1998-07-16 2003-04-01 Intel Corporation Method and apparatus for managing temporal and non-temporal data in a single cache structure
US6093734A (en) 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
HUP0202431A3 (en) * 1999-04-09 2003-03-28 Basf Ag Prodrugs of thrombin inhibitors
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
EP1334104A2 (en) * 2000-07-07 2003-08-13 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions
EP1334971A4 (en) 2000-10-12 2004-05-12 Takeda Chemical Industries Ltd BENZIMIDAZOLE COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF
US7129261B2 (en) * 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
US20040248941A1 (en) 2001-09-25 2004-12-09 Keiji Kamiyama Benzimidazone compound, process for producing the same, and use thereof

Also Published As

Publication number Publication date
CN1678315A (zh) 2005-10-05
BR0311801A (pt) 2005-04-12
US20050222210A1 (en) 2005-10-06
PL373085A1 (en) 2005-08-08
MXPA04012396A (es) 2005-06-17
US7410981B2 (en) 2008-08-12
WO2003106429A1 (ja) 2003-12-24
EP1513527B1 (en) 2009-07-29
DE60328603D1 (de) 2009-09-10
EP1514870A1 (en) 2005-03-16
PE20040563A1 (es) 2004-10-21
OA12867A (en) 2006-09-15
CA2489470A1 (en) 2003-12-24
AR040221A1 (es) 2005-03-16
KR20050009751A (ko) 2005-01-25
JPWO2003106429A1 (ja) 2005-10-13
NO20050141L (no) 2005-01-27
TW200307544A (en) 2003-12-16
NO20050141D0 (no) 2005-01-11
AU2003242390A1 (en) 2003-12-31
CA2489361A1 (en) 2003-12-24
ATE437642T1 (de) 2009-08-15
AU2003242388A1 (en) 2003-12-31
US20060293371A1 (en) 2006-12-28
EP1513527A1 (en) 2005-03-16
WO2003105845A1 (en) 2003-12-24
EP1514870A4 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
NO20050141D0 (no) Prodrugs av imidazolderivater for anvendelse som protonpumpeinhibitorer ved behandlingen av f.eks. peptisk ulcus
AU2003213768A1 (en) Use of benzimidazole analogs in the treatment of cell proliferation
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
WO2010038086A8 (en) P38 map kinase inhibitors
UA104731C2 (xx) Інгібітори р38 мар-кіназ$ингибиторы р38 мар-киназ
EP1803709A4 (en) PROTON PUMP INHIBITORS
AU2003258441A1 (en) System for performing proton therapy
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
AU2003301302A1 (en) Pyradazine compounds as gsk-3 inhibitors
AU2002306601A1 (en) Under the counter water treatment system
EP1534278A4 (en) NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
WO2007120333A3 (en) Tetracyclic kinase inhibitors
AU2002366796A8 (en) Methods using proton pump inhibitors
NO20054053D0 (no) Triazolforbindelser anvendbare i terapi.
HK1072379A1 (en) Annelated pyrrole compounds as proton pump inhibitors for treating ulcer
PL1626736T3 (pl) Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego
PL377464A1 (pl) Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN
WO2004098599A3 (en) Proton pump inhibitors for the treatment of lower abdominal disorders
TW200509921A (en) Alkaline salts
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
MY140194A (en) Novel fusidic acid derivatives
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
WO2003043614A3 (en) Reversible proton pump inhibitors for the treatment of airway disorders
WO2003075926A8 (en) Use of proton pump inhibitors for the treatment of airway disorders
AU2001291604A1 (en) Use of proton pump inhibitors for treating diseases of the locomotor system